Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioAtla (BCAB) EBITDA Margin (2020 - 2025)

BioAtla (BCAB) has disclosed EBITDA Margin for 4 consecutive years, with 462.75% as the latest value for Q4 2025.

  • For Q4 2025, EBITDA Margin changed N/A year-over-year to 462.75%; the TTM value through Dec 2025 reached 2965.25%, down 229304.0%, while the annual FY2025 figure was 2965.25%, 229304.0% down from the prior year.
  • EBITDA Margin hit 462.75% in Q4 2025 for BioAtla, down from 102.45% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 102.45% in Q3 2024 and bottomed at 12184.0% in Q2 2021.
  • Average EBITDA Margin over 3 years is 4249.73%, with a median of 462.75% recorded in 2025.
  • On a YoY basis, EBITDA Margin climbed as much as -980505bps in 2021 and fell as far as -980505bps in 2021.
  • BioAtla's EBITDA Margin stood at 12184.0% in 2021, then surged by 99bps to 102.45% in 2024, then crashed by -352bps to 462.75% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 462.75%, 102.45%, and 12184.0% for Q4 2025, Q3 2024, and Q2 2021 respectively.